Double Blind, Randomized, Phase II Clinical Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET Versus Vehicle Control in Dystrophic Epidermolysis Bullosa (DEB) Patients
Latest Information Update: 24 Apr 2024
At a glance
- Drugs Adipose stem cell therapy Anterogen (Primary)
- Indications Epidermolysis bullosa dystrophica
- Focus Adverse reactions
- Sponsors Anterogen
Most Recent Events
- 19 Apr 2024 Planned End Date changed from 28 Feb 2025 to 28 Apr 2026.
- 19 Apr 2024 Planned primary completion date changed from 1 Nov 2024 to 1 Oct 2025.
- 23 Aug 2023 Status changed from not yet recruiting to recruiting.